NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.00 0.00 (0.00 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$18.00
Today's Range$18.00 - $18.00
52-Week Range$9.30 - $18.75
Volume303,068 shs
Average Volume2.56 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SCMP
Previous Symbol
CUSIP86490910
Phone+1-301-9613400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees139
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. The biopharmaceutical company had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals's revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.30 earnings per share. View Sucampo Pharmaceuticals' Earnings History.

What price target have analysts set for SCMP?

7 equities research analysts have issued 12-month target prices for Sucampo Pharmaceuticals' shares. Their forecasts range from $15.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $21.6667 in the next year. This suggests a possible upside of 20.4% from the stock's current price. View Analyst Price Targets for Sucampo Pharmaceuticals.

What is the consensus analysts' recommendation for Sucampo Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sucampo Pharmaceuticals in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sucampo Pharmaceuticals.

Has Sucampo Pharmaceuticals been receiving favorable news coverage?

Media stories about SCMP stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:
  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

How do I buy shares of Sucampo Pharmaceuticals?

Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of SCMP stock can currently be purchased for approximately $18.00.

What is Sucampo Pharmaceuticals' official website?

The official website for Sucampo Pharmaceuticals is http://www.sucampo.com.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  534
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel